CY1110981T1 - Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα - Google Patents

Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα

Info

Publication number
CY1110981T1
CY1110981T1 CY20101101127T CY101101127T CY1110981T1 CY 1110981 T1 CY1110981 T1 CY 1110981T1 CY 20101101127 T CY20101101127 T CY 20101101127T CY 101101127 T CY101101127 T CY 101101127T CY 1110981 T1 CY1110981 T1 CY 1110981T1
Authority
CY
Cyprus
Prior art keywords
description
allergyogenes
peptides
preventing
allergy
Prior art date
Application number
CY20101101127T
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of CY1110981T1 publication Critical patent/CY1110981T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Η παρούσα εφεύρεση σχετίζεται με πεπτίδια που περιλαμβάνουν πολλά επίτοπα Τ κυττάρων σύνδεσης με MHC Κλάσης ΙΙ για θεραπεία δημιουργίας ανεκτικότητας.
CY20101101127T 2007-08-15 2010-12-07 Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα CY1110981T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
EP08788348A EP2083856B1 (en) 2007-08-15 2008-08-15 Peptides for desensibilization against allergens

Publications (1)

Publication Number Publication Date
CY1110981T1 true CY1110981T1 (el) 2015-06-11

Family

ID=40134075

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101101127T CY1110981T1 (el) 2007-08-15 2010-12-07 Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα
CY20151100901T CY1116828T1 (el) 2007-08-15 2015-10-07 Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100901T CY1116828T1 (el) 2007-08-15 2015-10-07 Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα

Country Status (24)

Country Link
US (7) US8652485B2 (el)
EP (4) EP2083856B1 (el)
JP (3) JP5697447B2 (el)
KR (1) KR101699554B1 (el)
CN (2) CN101820907B (el)
AT (1) ATE482721T1 (el)
AU (1) AU2008288283B2 (el)
BR (1) BRPI0815395A2 (el)
CA (1) CA2696563A1 (el)
CY (2) CY1110981T1 (el)
DE (1) DE602008002810D1 (el)
DK (2) DK2083856T3 (el)
EA (2) EA018110B1 (el)
ES (1) ES2402956T3 (el)
HK (2) HK1132194A1 (el)
HR (2) HRP20100662T1 (el)
IL (1) IL203943A (el)
MX (1) MX2010001779A (el)
NZ (2) NZ583362A (el)
PL (1) PL2083856T3 (el)
PT (2) PT2083856E (el)
SI (2) SI2190473T1 (el)
WO (4) WO2009022156A2 (el)
ZA (2) ZA201001056B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CN101820907B (zh) * 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
SI2153841T2 (sl) 2008-08-15 2016-02-29 Circassia Limited Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
NZ594268A (en) 2009-02-05 2013-05-31 Circassia Ltd Grass peptides for vaccine
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
US9975932B2 (en) 2010-01-14 2018-05-22 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
EP3662916A1 (en) * 2010-06-03 2020-06-10 ALK-Abelló A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
ES2561825T3 (es) * 2010-09-24 2016-03-01 María R. Díaz-Torres Péptidos
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
EA027410B1 (ru) 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов
CN103748105A (zh) * 2011-06-15 2014-04-23 生物技术工具公司 一种生产水解过敏原的方法
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
WO2014066939A1 (en) 2012-10-30 2014-05-08 Monash University Novel immunotherapeutic molecules and uses thereof
CN105338968A (zh) 2013-05-03 2016-02-17 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
WO2014195382A1 (en) * 2013-06-05 2014-12-11 Alergenetica Sl T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
DK3003366T3 (da) * 2013-06-06 2020-10-26 Anergis S A På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider
RU2689552C2 (ru) * 2013-09-25 2019-05-28 Аравакс Пти Лтд Новая иммунотерапевтическая композиция и ее применения
WO2015100360A1 (en) * 2013-12-23 2015-07-02 Alk-Abelló A/S Peptide combinations and uses thereof in treating dust mite allergy
CN106132996B (zh) 2014-03-31 2020-10-09 勃林格殷格翰动物保健有限公司 经改良的模块化抗原转运分子及其用途
CA2957737A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3279218A4 (en) * 2015-03-30 2018-12-05 Osaka University Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disorders containing same, and method for treating immune disorders
US10898568B2 (en) 2015-09-30 2021-01-26 Boehringer Ingelheim Vetmedica Gmbh Modular antigen transportation molecules and uses thereof in animals
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
EP3654778A1 (en) 2017-07-18 2020-05-27 Before Brands, Inc. Methods for making mixed allergen compositions
US10596270B2 (en) * 2017-09-18 2020-03-24 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
WO2020154476A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) * 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
EP0362290A4 (en) * 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
DK0500785T3 (da) 1989-11-03 2002-08-19 Immulogic Pharma Corp Humant T-celleaktivitet felint protein (TRFP) isoleret fra husstøv samt anvendelser heraf
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
CA2091449C (en) * 1990-09-11 2002-11-05 Wayne R. Thomas Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
DE69233772D1 (de) 1991-10-16 2009-11-12 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6696061B1 (en) 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
AU664920B2 (en) 1992-08-14 1995-12-07 Asahi Breweries, Ltd. Peptide having allergenicity
CA2152818A1 (en) * 1992-12-31 1994-07-21 Jay P. Morgenstern Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
EP0688338A1 (en) 1993-03-12 1995-12-27 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
JPH09501043A (ja) * 1993-04-14 1997-02-04 イミュロジク ファーマスーティカル コーポレイション Ｄｅｒｍａｔｏｐｈａｇｏｉｄｅｓ（室内塵ダニ）由来の主要アレルゲンのｔ細胞エピトープ
WO1994027634A1 (en) 1993-06-02 1994-12-08 Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
JPH09504167A (ja) 1993-08-13 1997-04-28 イミュロジック ファーマスーティカル コーポレイション ドクムギ花粉アレルゲンのｔ細胞エピトープ
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
KR100379161B1 (ko) * 1994-04-14 2003-06-11 이뮤로직 파마시티컬 코포레이션 집먼지진드기에의한알레르기를치료하기위한의학적펩티드조성물
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999034826A1 (en) 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
HU229377B1 (hu) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
MXPA03004174A (es) * 2000-11-16 2004-12-02 Alk Abello As Alergenos mutantes novedosos.
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) * 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) * 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
US20040071718A1 (en) 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
US8198401B2 (en) 2003-03-07 2012-06-12 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis
WO2005000891A2 (en) 2003-06-26 2005-01-06 Merck Patent Gmbh Thrombopoietin proteins with improved properties
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
EP1685160A1 (en) 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
WO2005103082A2 (en) 2004-04-23 2005-11-03 Novozymes A/S Group 1 mite polypeptide variants
WO2005121166A1 (en) * 2004-06-10 2005-12-22 Monash University Novel immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
CN101044244B (zh) 2004-09-27 2010-05-05 株式会社林原生物化学研究所 异环麦芽寡糖和异环麦芽寡糖合酶以及其制备方法和用途
EP1843779A2 (en) 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
JP2009508118A (ja) 2005-09-15 2009-02-26 アルク−アベッロ エイ／エス アレルゲンの定量方法
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
PT2476435T (pt) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CN101820907B (zh) * 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
WO2009067191A2 (en) * 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
ZA201001056B (en) 2011-04-28
HRP20100662T1 (hr) 2011-01-31
PL2083856T3 (pl) 2011-04-29
CN103272227B (zh) 2014-12-10
CA2696563A1 (en) 2009-02-19
PT2083856E (pt) 2010-12-23
US8652485B2 (en) 2014-02-18
US20160289281A1 (en) 2016-10-06
MX2010001779A (es) 2010-07-06
WO2009022157A2 (en) 2009-02-19
WO2009022156A3 (en) 2009-04-30
JP2010536333A (ja) 2010-12-02
US20110123558A1 (en) 2011-05-26
ATE482721T1 (de) 2010-10-15
BRPI0815395A2 (pt) 2015-02-10
SI2190473T1 (sl) 2013-05-31
HK1132194A1 (en) 2010-02-19
CN101820907A (zh) 2010-09-01
WO2009022154A2 (en) 2009-02-19
US20100298239A1 (en) 2010-11-25
ZA201001054B (en) 2011-04-28
EP2397154A3 (en) 2012-04-04
WO2009022155A2 (en) 2009-02-19
DK2190473T3 (da) 2013-03-25
PT2397154E (pt) 2015-10-29
US20170157226A1 (en) 2017-06-08
EP2286833A2 (en) 2011-02-23
EP2397154B1 (en) 2015-07-15
US9744222B2 (en) 2017-08-29
EP2190473B1 (en) 2013-01-16
HRP20130270T1 (hr) 2013-04-30
EA018110B1 (ru) 2013-05-30
NZ583361A (en) 2012-10-26
IL203943A (en) 2013-05-30
SI2083856T1 (sl) 2011-02-28
JP6040207B2 (ja) 2016-12-07
JP5697447B2 (ja) 2015-04-08
JP2015057393A (ja) 2015-03-26
EP2190473A2 (en) 2010-06-02
EP2083856A2 (en) 2009-08-05
WO2009022157A3 (en) 2009-06-04
CN101820907B (zh) 2013-05-01
EP2397154A2 (en) 2011-12-21
NZ583362A (en) 2012-06-29
ES2402956T3 (es) 2013-05-10
WO2009022154A3 (en) 2009-06-04
EA023303B1 (ru) 2016-05-31
US8551493B2 (en) 2013-10-08
CN103272227A (zh) 2013-09-04
WO2009022156A2 (en) 2009-02-19
US20130336999A1 (en) 2013-12-19
KR101699554B1 (ko) 2017-01-25
EP2286833A3 (en) 2011-09-14
JP2017061455A (ja) 2017-03-30
CY1116828T1 (el) 2017-03-15
US20140186403A1 (en) 2014-07-03
EA201070270A1 (ru) 2010-08-30
AU2008288283A1 (en) 2009-02-19
AU2008288283B2 (en) 2013-01-31
US9340580B2 (en) 2016-05-17
HK1164700A1 (en) 2012-09-28
US20100260805A1 (en) 2010-10-14
WO2009022155A3 (en) 2009-06-04
DK2083856T3 (da) 2011-01-24
DE602008002810D1 (de) 2010-11-11
KR20100068252A (ko) 2010-06-22
EA201070271A1 (ru) 2010-12-30
EP2083856B1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
CY1110981T1 (el) Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
NL300915I2 (nl) Daratumumab
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
BRPI0720328A2 (pt) Composição tensoativa e detergente ou limpador.
FI20055622A0 (fi) Järjestely pölyn käsittelemiseksi
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE504334T1 (de) Haarbehandlungszusammensetzungen
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
ATE474886T1 (de) Polythioether-aminharze und zusammensetzungen damit
MX2011008179A (es) Peptidos para vacuna.
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
DE602006010424D1 (de) Schweisshemmende oder desodorierende zusammensetzungen
MX2009007929A (es) Uso de un primer alergeno del grupo 2 de acaro de polvo de casa para tratar alergia a un segundo alergeno del grupo 2 de acaro de polvo de casa.
ATE536033T1 (de) Vlan-nummerierung in zugangsnetzen
EA201201402A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
AT503071A3 (de) Pflanzenkläranlage
FI20055163A0 (fi) Hoitopöytä